Small-cap med-tech stock AngioDynamics (ANGO)
continues to offer the sort of patience-testing value opportunity that
drives many investors away in frustration. That said, a rebound in the
company's laser-based varicose vein treatment and synergies from the
Navilyst deal do give patient investors a little encouragement for the
short-term.
Please click here for more:
AngioDynamics Still A "Hurry Up And Wait" Story
No comments:
Post a Comment